未登录

Z

Zhengyu Yang

South China University of Technology

H指数:0

被引数:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bioactive glass nanoparticle-induced osteogenesis via lncRNA Gm16263/Taok3 axis facilitates Gm16263-loaded EV bone regeneration therapy

生物活性玻璃纳米粒子通过lncRNA Gm16263/Taok3轴诱导的成骨作用促进Gm16263负载外泌体的骨再生疗法

Regenerative Biomaterials

IF8.1

2026-09-290

OAAI

Genome-wide analysis and identification of microRNAs in Medicago truncatula under aluminum stress

FRONTIERS IN PLANT SCIENCE

IF4.8

2023-01-276

OAAI

Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2022-05-115

PRE

ASO Visual Abstract: Different Characteristics and Survival Between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma Differences between P-LCNEC and C-LCNEC

ANNALS OF SURGICAL ONCOLOGY

IF3.5

2022-04-190

PRE

Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2022-02-1413

OAAI

Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

IF3

2022-02-118

OA

Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung

FRONTIERS IN ONCOLOGY

IF3.3

2021-09-225

OAAI

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

FRONTIERS IN IMMUNOLOGY

IF5.9

2021-09-1711

OAAI

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations

FRONTIERS IN ONCOLOGY

IF3.3

2021-08-1612

OAAI

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-288

OAAI

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer

非小细胞肺癌中共同发生的潜在可行的致癌驱动因素

FRONTIERS IN ONCOLOGY

IF3.3

2021-06-1616

OAAI

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC

Pembrolizumab加化疗或安洛替尼与单用Pembrolizumab在先前治疗过的EGFR突变型NSCLC患者中的比较

FRONTIERS IN ONCOLOGY

IF3.3

2021-04-1624

OAAI

Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

IF3

2020-11-1711

OAAI